Skip to main content

Table 2 Relative dose intensity, dose reduction and delay of the nal-IRI plus 5-FU/LV

From: Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study

 

nal-IRI plus 5-FU/LV (n = 51)

Median duration of treatment, months (range)

1.9 (0.5–7.0)

Median cycles of treatment, n (range)

4 (2–12)

Median relative dose intensity, n (range)

0.87 (0.54–1.00)

RDI ≥ 85%, n (%)

36 (70.6)

RDI < 85%, n (%)

15 (29.4)

Dose reduction in first 3 cycles, n (%)

30 (58.8)

Dose delay in first 3 cycles, n (%)

13 (25.5)

  1. Nal-IRI nanoliposomal irinotecan, 5-FU/LV fluorouracil/folinic acid, RDI relative dose intensity